B&L Expanded Drug-Delivery Products Seen As Springboard To Future Growth
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb continues to transform itself into a drug-delivery eyecare company from a traditional contact lens firm, with implants and molecular compounds in various stages of development
You may also be interested in...
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull